Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Real-Time Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
03320 CHINARES PHARMA
RTNominal down7.100 -0.030 (-0.421%)
Others

29/11/2019 09:55

CR Pharma's (03320) heart attack drug included in NRDL

[ET Net News Agency, 29 November 2019] China Resources Pharmaceutical Group Limited
(03320) said its biopharmaceutical drug, Rui Tong Li (commonly known as "Reteplase",
Reteplase (rPA) for InJection) has undergone evaluation for inclusion in the 2019 National
Reimbursement Drug List (NRDL) with assessment of a high pharmacoeconomic value resulting
in inclusion within the list.
Rui Tong Li is produced by China Resources AngDe Biotech Pharma Co., Ltd, a controlling
subsidiary of the group's biopharmaceutical platform. The drug is used to treat acute
myocardial infarction, effectively reducing the mortality rate, and aiding patient
recovery.
Rui Tong Li is the first third-generation specific thrombolytic agent launched in China,
and the only one included in the 2018 National Essential Medicine List among all specific
thrombolytic agents due to its outstanding clinical results.
Rui Tong Li recorded an annual turnover of RMB50 million in 2018, occupying around 3.5%
of the market of thrombolytic products. In the future, relying on policy support from
being included in the National Essential Medicines List and the NRDL, combining with the
product's comprehensive clinical efficacy and price advantages, the group expects that the
annual sales of Rui Tong Li will be likely to exceed RMB200 million. (KL)

Remark: Real time quote last updated: 20/01/2020 11:37
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2020 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.